Thursday - April 23, 2026

Focal Segmental Glomerulosclerosis Market to Surpass USD 837 Million by 2034, Growing at a Steady CAGR from USD 734 Million in 2022, Driven by Novel Therapies, Rising Prevalence | DelveInsight

Focal Segmental Glomerulosclerosis Market Key companies actively involved in the Focal Segmental Glomerulosclerosis (FSGS) market include Travere Therapeutics, Dimerix, Goldfinch Bio, Vertex Pharmaceuticals, GlaxoSmithKline, Dimerix Bioscience Pty Ltd, ChemoCentryx, AstraZeneca, Genentech, Inc., Sanofi, Mallinckrodt ARD LLC, ACELYRIN Inc., Kyowa Kirin … Continue reading

EMPAVELI Sales Forecast to 2034 Signals Strong Growth Across PNH and Rare Kidney Diseases, Driven by C3 Inhibition Advantage and Expanding Indication Landscape | DelveInsight

EMPAVELI Sales The global rare disease therapeutics landscape is undergoing a profound transformation, and at the center of this evolution is EMPAVELI (pegcetacoplan) – a first-in-class complement C3 inhibitor that is redefining treatment paradigms across hematology and nephrology. According to … Continue reading

Psoriatic Arthritis Market to Exceed USD 15 Billion by 2034 with 20+ Emerging Therapies and Strong Clinical Advancements from UCB Biopharma, Bristol Myers Squibb, and Sun Pharmaceutical | DelveInsight

Psoriatic Arthritis Market Leading Psoriatic Arthritis companies working in the market are UCB Biopharma, Sun Pharmaceutical Industries Limited, BMS, Affibody AB, Janssen Biotech, Amgen, Eli Lilly and Company, Teva Pharma, Boehringer Ingelheim, AbbVie, Roche, Ampio Pharmaceuticals, Antares Pharma, Currax Pharmaceuticals, … Continue reading